Clopidogrel before elective percutaneous coronary intervention

J Clin Pharmacol. 2010 Apr;50(4):373-9. doi: 10.1177/0091270009348975. Epub 2009 Sep 29.

Abstract

The introduction of percutaneous coronary intervention (PCI) substantially changed the treatment of patients with coronary artery disease. Stent thrombosis is the most worrisome early complication in patients undergoing PCI. Therefore, antiplatelet therapy forms an integral component of treatment with intracoronary stent implantation. A multitude of randomized and observational studies have helped identify and define the role of clopidogrel in today's PCI patient. Although much is known about its use, a number of questions still remain.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary* / adverse effects
  • Clopidogrel
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / surgery
  • Elective Surgical Procedures*
  • Humans
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Preoperative Care* / methods
  • Randomized Controlled Trials as Topic / methods
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Clopidogrel
  • Ticlopidine